Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial
Wen‐Fei Li, Nian‐Yong Chen, Ning Zhang et al. · International Journal of Cancer · 2019
To report long‐term results of a randomized controlled trial that compared cisplatin/fluorouracil/docetaxel (TPF) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with stage III–IVB (except T3–4 N0) NPC were randomly assigned to receive IC plus CCRT (n = 241) or CCRT alone (n = 239). IC included three cycles of docetaxel (60 mg/m 2 d1), cisplatin (60 mg/m 2 d1), and fluorouracil (600 mg/m 2 /d civ d1–5) every 3 weeks. Patients from both groups received intensity‐modulated radiotherapy concurrently with three cycles of 100 mg/m 2 cisplatin every 3 weeks. After a median follow‐up of 71.5 months, the IC plus CCRT group showed significantly better 5‐year failure‐free survival (FFS, 77.4% vs . 66.4%, p = 0.019), overall survival (OS, 85.6% vs . 77.7%, p = 0.042), distant failure‐free survival (88% vs . 79.8%, p = 0.030), and locoregional failure‐free survival (90.7% vs . 83.8%, p = 0.044) compared to the CCRT alone group. Post hoc subgroup analyses revealed that beneficial effects on FFS were primarily observed in patients with N1, stage IVA, pretreatment lactate dehydrogenase ≥170 U/l, or pretreatment plasma Epstein–Barr virus DNA ≥6000 copies/mL. Two nomograms were further developed to predict the potential FFS and OS benefit of TPF IC. The incidence of grade 3 or 4 late toxicities was 8.8% (21/239) in the IC plus CCRT group and 9.2% (22/238) in the CCRT alone group. Long‐term follow‐up confirmed that TPF IC plus CCRT significantly improved survival in locoregionally advanced NPC with no marked increase in late toxicities and could be an option of treatment for these patients.
Cited by 251 works. doi:10.1002/ijc.32099
Authors
- Wen‐Fei Li
- Nian‐Yong Chen
- Ning Zhang
- Guoqing Hu
- Fang‐Yun Xie
- Yan Ping Sun
- Yan Ping Sun
- Xiaozhong Chen
- Jingao Li
- Xiaodong Zhu
- Chaosu Hu
- Xiangying Xu
- Yuan‐Yuan Chen
- Wei‐Han Hu
- Ling Jun Guo
- Hao‐Yuan Mo
- Lei Chen
- Yan‐Ping Mao
- Rui Sun
- Ping Ai
References
- Regression Models and Life-Tables
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
- Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience
- Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
- Quantification of Plasma Epstein–Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma
- Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial